Capital International Investors Acquires 1,478,076 Shares of Abbott Laboratories $ABT

Capital International Investors raised its holdings in Abbott Laboratories (NYSE:ABT) by 2.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 61,614,739 shares of the healthcare product maker’s stock after acquiring an additional 1,478,076 shares during the quarter. Abbott Laboratories makes up about 1.3% of Capital International Investors’ portfolio, making the stock its 18th largest holding. Capital International Investors owned about 3.54% of Abbott Laboratories worth $8,251,974,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ABT. Brighton Jones LLC increased its stake in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares during the period. Sivia Capital Partners LLC lifted its holdings in Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares during the period. United Bank boosted its position in Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after acquiring an additional 2,001 shares during the last quarter. AE Wealth Management LLC grew its holdings in Abbott Laboratories by 27.3% during the 2nd quarter. AE Wealth Management LLC now owns 54,240 shares of the healthcare product maker’s stock worth $7,377,000 after acquiring an additional 11,630 shares during the period. Finally, AGF Management Ltd. raised its position in shares of Abbott Laboratories by 13.2% in the 2nd quarter. AGF Management Ltd. now owns 24,520 shares of the healthcare product maker’s stock worth $3,335,000 after acquiring an additional 2,850 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 2.9%

NYSE ABT opened at $112.69 on Tuesday. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $139.15. The business has a 50 day moving average price of $115.86 and a 200-day moving average price of $124.44. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The company has a market cap of $195.82 billion, a price-to-earnings ratio of 30.29, a P/E/G ratio of 1.74 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the firm posted $1.34 EPS. Abbott Laboratories’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Insider Activity

In other news, EVP Mary K. Moreland sold 613 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the sale, the executive vice president directly owned 104,291 shares of the company’s stock, valued at $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares in the company, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 3,055 shares of company stock worth $353,097. Company insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ABT shares. Evercore cut their target price on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Argus dropped their target price on shares of Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Oppenheimer reduced their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, BTIG Research decreased their price target on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $136.37.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.